Sernova
@SernovaCorp
Followers
2,261
Following
837
Media
197
Statuses
570
Sernova (TSX: SVA, $SEOVF) is advancing a novel cell therapy platform for chronic diseases including type 1 diabetes, hemophilia A, and hypothyroidism.
London, Ontario
Joined September 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#KawalPutusanMK
• 3995389 Tweets
#TolakPolitikDinasti
• 2386204 Tweets
FB JOIN OPENING BTV HOUSE
• 574108 Tweets
BATALKAN BUKAN TUNDA
• 421191 Tweets
Mulyono
• 263702 Tweets
#TolakPilkadaAkal2an
• 124862 Tweets
#NHK_MUSICEXPO
• 123094 Tweets
South Africans
• 95360 Tweets
FOTFOT NEW SINGLE
• 87119 Tweets
中川大志
• 27656 Tweets
BGYO TRASH OUT NOW
• 24915 Tweets
#GOATなINZM
• 16924 Tweets
ドラゴンズ
• 16011 Tweets
サヨナラ
• 15807 Tweets
オリックス
• 15521 Tweets
勝ち越し
• 14941 Tweets
ベイスターズ
• 12075 Tweets
ちいかわ寿司
• 11021 Tweets
Today, we announced new positive interim data from our ongoing Phase 1/2 clinical trial evaluating our novel
#CellTherapy
platform in people living with
#Type1Diabetes
(
#T1D
). Read our press release to learn more: $SEOVF $SVA
#Diabetes
5
46
109
Today, we announced a preclinical research collaboration with
@AstraZeneca
to evaluate the use of our Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells. Read our press release for more details:
8
34
90
Stay tuned for more of Sernova's Cell Pouch System Phase I/II Clinical Trial updates.
Patient No. 1 now at 20 months insulin free after 47 years with type 1 diabetes and hypoglycemia unawareness.
Visit for our latest presentation.
8
20
79
At Sernova, we are developing a novel
#CellTherapy
platform for the potential treatment of chronic diseases including insulin-dependent
#diabetes
,
#hypothyroidism
, and
#hemophiliaA
. Learn more about our programs in development: $SEOVF $SVA
1
40
68
Our Cell Pouch System™ is a proprietary cell therapy platform being developed for the treatment of chronic diseases including insulin-dependent
#diabetes
,
#HemophiliaA
, and
#hypothyroidism
. Learn more:
#T1D
#Type1Diabetes
$SVA $SEOVF
6
36
67
Check out this
@endpts
article which highlights our novel
#CellTherapy
platform and the progress we’ve made towards a ‘functional cure’ for
#T1D
. Our CEO, Cynthia Pussinen, discussed that and more with
@KatherineMLewin
. Read the story here: $SEOVF
1
32
68
Dr. Philip Toleikis, President & CEO, Sernova Corp presenting, between his business meetings, to over 250 attendees during the Sernova session at the Cell & Gene Meeting on the Med today in Barcelona.
2
7
72
We were joined by
@MarekCTV
of
@CTVLondon
at our office and lab in London, Ontario, to discuss our interim clinical data presented at
#ADA2023
and the advancement of our Cell Pouch System™ as a potential ‘functional cure’ for
#T1D
. Watch the interview:
2
35
62
An exciting and heart-warming testimonial from the first patient enrolled in our Phase I/II clinical trial. As we progress through our clinical study, we’re committed to providing a “functional cure”, via our Cell Pouch System ™️ for all patients affected by T1D. ❤️
#diabetes
9
28
75
According to
@CDCgov
,
#diabetes
is the 8th leading cause of death in the United States. Estimates project that 1.9 million Americans are living with
#Type1Diabetes
. Sernova is committed to advancing a potential ‘functional cure’ for
#T1D
. Learn more here:
4
37
59
Our partners at
@Evotec
have developed a differentiated GMP manufacturing process that allows for the commercial-scale production of induced pluripotent stem cell-derived islet-like clusters for use in our Cell Pouch System™. Check out the graphic below for more details!
3
30
67
At
#ADA2023
, our investigators from
@UChicagoMed
shared positive updated interim data from the first cohort and updates from the second cohort of our ongoing Phase 1/2 clinical trial in people with
#T1D
. Read our press release to learn more: $SVA $SEOVF
4
28
60
We are excited to announce Cynthia Pussinen as our newly appointed
#CEO
. Her extensive
#biopharma
industry
#leadership
experience will be vital as we advance our
#CellTherapy
platform as a treatment for chronic diseases. Learn more here: $SVA $SEOVF
1
27
63
Insulin is one way the body controls glucose. Pancreatic islets are made of alpha, beta, and delta cells, which each secrete a hormone that helps to regulate blood glucose.
@Evotec
’s iPSC-derived ILCs mimic the function of human pancreatic islets. See the graphic below for more!
3
32
64
In addition to our program for insulin-dependent
#diabetes
, we are evaluating our novel
#CellTherapy
platform as a potential treatment for chronic diseases including
#hypothyroidism
and
#HemophiliaA
. Learn more about our pipeline here: $SVA $SEOVF
1
31
61
Today at the 2023
@AmThyroidAssn
Annual Meeting, we presented new preclinical data evaluating our novel cell therapy platform as a potential treatment for post-operative
#hypothyroidism
. Learn more about the data here: $SVA $SEOVF
1
33
57
We welcome Modestus Obochi, PhD, MBA, to our
#leadership
team as
#ChiefBusinessOfficer
. His expertise in business development & strategy will be vital as we continue to work toward a potential ‘functional cure’ for chronic diseases. Read more: $SVA $SEOVF
1
36
54
Members of our leadership team will be at the
@alliancerm
’s
#CGMesa23
in Carlsbard, California, from October 10-12. We look forward to connecting with other industry leaders about our novel
#CellTherapy
platform for chronic diseases. Register here:
0
29
56
#ICYMI
, check out this
@CGT_Live
article by Noah Stansfield about the positive updated interim data presented at
#ADA2023
from our Phase 1/2 study in people with
#Type1Diabetes
(
#T1D
) who have severe hypoglycemia unawareness. Read more here: $SVA $SEOVF
2
36
56
Our VP of Clinical Development and Reg. Affairs, Frank Shannon, and our CBO, Modestus Obochi, PhD, MBA, will be at
#EASD2023
! Our team is looking forward to talking with potential strategic partners about our novel
#CellTherapy
platform. Register here:
0
27
58
Through our collaboration with
@AliceTomei79
of
@umiamimedicine
, we have advanced our conformal coating technology in combination with our Cell Pouch™. Learn more about the progress of our product development by reading our press release: $SVA $SEOVF
0
18
58
We have received conditional approval to up-list from the TSX Venture Exchange (TSXV) to the Toronto Stock Exchange (TSX). Read our press release to learn more: $SVA
3
14
64
Our Cell Pouch System™ (CPS) is designed to allow natural vascularization and the free exchange of proteins and hormones. As an organ-like environment that fosters long-term cell survival, the CPS has applications in multiple chronic diseases. Learn more:
5
13
61
Our collaborators, Dr. Piotr Witkowski of
@UChicagoMed
, and
@AliceTomei79
of
@umiamimedicine
, will be present data and development updates for our technologies at the IPITA-IXA-CTRMS Joint Congress in San Diego, Oct. 26-29. Details here: $SEOVF
0
30
53
At Sernova, we are advancing our Cell Pouch System™ with the goal of improving the quality of life for patients with chronic diseases including
#Type1Diabetes
,
#Hypothyroidism
, and
#HemophiliaA
. Learn more about our
#CellTherapy
approach on our website:
1
27
54
📰 The U.S. FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation for our program evaluating our novel
#CellTherapy
platform in
#HemophiliaA
! 🧬 And that’s not all. Explore our new collaboration with
@UniAvogadro
here: $SEOVF $SVA
0
15
59
Reminder – Sernova will host a webcast tomorrow, October 5, to provide a business update and discuss strategy and operation plans moving forward. Sign up to join the webcast here: $SVA $SEOVF
0
31
52
Please stay tuned...Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial on Jan 10 as ASTS Conference is cancelled due to Covid!
10
11
61
We have received approval from the
@UChicagoMed
IRB, with no objections from the US FDA, to enroll patients in a 2nd cohort of our Ph1/2 study in
#Type1Diabetes
patients who suffer severe hypoglycemic episodes and
#HypoglycemiaUnawareness
. Learn more:
#T1D
4
15
59
Today, we announced new advancements from the preclinical evaluation of our immune-protection technology in combination with our novel
#CellTherapy
platform, the Cell Pouch System™. Learn more here: $SVA $SEOVF
#Type1Diabetes
#T1D
#Diabetes
0
14
57
In the latest
@pharmasalmanac
roundtable article, our CEO Dr. Philip Toleikis shared how an increased focus on patient-centric concerns is influencing the development of our
#CellTherapy
approach to treating
#T1D
and other chronic diseases. Read here:
2
35
48
#ClinicalData
from the Phase 1/2 trial of the Cell Pouch System being conducted by Dr. Piotr Witkowski will be presented by Dr. Piotr Jerzy Bachul of
@UChicagoMed
at the
@AmDiabetesAssn
82nd Scientific Sessions next week. Learn more:
#ADA2022
1
14
52
The diabetes cure: A century after Banting and Best’s ‘message of hope,’ science is actually close via
@torontostar
7
13
55
The first two patients in the second cohort of our Phase 1/2 clinical trial for
#T1D
have received the first islet transplantation in our 10-channel Cell Pouch. Additionally, a third patient in the second cohort received the Cell Pouch implant. Read more:
2
8
56
Our Cell Pouch System is designed for the long-term survival and function of therapeutic cells to treat chronic diseases including
#T1D
,
#Hypothyroidism
and
#HemophiliaA
. Learn more about our device here:
2
9
56
Chelsea Stellick, research analyst at IA Capital Markets, initiated coverage of Sernova (TSX-V:SVA) (OTCQB:SEOVF) (FSE / XETRA:PSH) with a Buy rating and a target price of $3 a share.
3
12
54
#ICYMI
, an update from our Phase 1/2 study of our Cell Pouch with islet transplantation, our candidate in development for a potential ‘functional cure’ of insulin-dependent diabetes, was presented at the
@AmDiabetesAssn
82nd Scientific Session. Learn more:
7
11
55
Vote for our
#SXSW2024
presentation! We hope to discuss our work to develop a
#CellTherapy
that could eliminate the need for insulin shots & improve the lives of people living with
#Type1Diabetes
. Make a free profile & vote on
#PanelPicker
by Aug. 20:
#T1D
5
34
45
We are pleased to announce that our abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions, being held from June 3-7, 2022. Learn more here:
#ADA2022
5
7
55
Join us on June 24 at
@AmDiabetesAssn
's
#ADA2023
!
At 5:15 pm, our investigators from
@UChicagoMed
will share updated interim clinical data for our Cell Pouch System™.
At 6:30 pm, we're hosting an investor and analyst event. $SVA $SEOVF
Register now:
0
26
42
Sernova Announces Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A -
2
16
51
Don’t miss us at
#ADA2023
! Our investigators from
@UChicagoMed
will present updated interim data from the first cohort of our Phase 1/2 clinical trial in people living with
#T1D
and severe hypoglycemia unawareness. Learn more about the presentation here:
0
25
46
#ICYMI
, our collaborator, Dr. Alice Tomei of
@umiamimedicine
, discussed the advancements in conformal coating to overcome challenges associated with transplanting insulin-producing cells in the body. Learn more:
4
8
49
Our Cell Pouch System™️ is a fully retrievable payload device that is safe and well-tolerated. Learn more by reading our press release here:
4
13
53
We are thrilled to share an update from our
#CellTherapy
program for
#hypothyroidism
. Data from our preclinical study demonstrated the potential for our Cell Pouch System™ to treat post-thyroidectomy hypothyroidism. See the press release for details:
1
13
49
Today we shared a positive clinical update and announced plans to file an Investigational New Drug (IND) application with the U.S. FDA to advance clinical evaluation of our cell therapy platform in post-operative hypothyroidism. Learn more: $SVA $SEOVF
3
15
49
Today is
#WorldDiabetesDay
! This year’s theme is access to diabetes care, as millions of
#diabetes
patients lack adequate treatment. At Sernova, we’re developing a novel
#CellTherapy
platform for diabetes and other chronic diseases. Learn more here:
2
6
44
At Sernova, we are committed to providing a
#CellTherapeutic
as a potential ‘functional cure’ for chronic diseases including
#T1D
,
#Hypothyroidism
, and
#HemophiliaA
. Learn more about our therapeutic approach and Cell Pouch System here:
4
11
49
At Sernova, we're developing our novel
#CellTherapy
platform as a potential treatment for
#hypothyroidism
. In recognition of
#ThyroidAwarenessMonth
, we're encouraging our followers to visit the
@AmThyroidAssn
website to learn more about thyroid diseases:
1
13
49
On September 15, Cynthia Pussinen, our
#CEO
, and Dr. Modestus Obochi, our CBO, will be introduced during a webcast. On October 5, we will host another webcast to provide a business update. Learn how to join the webcasts here: $SVA $SEOVF
0
17
42
Solid Turnout for Sernova at Bloom Burton Healthcare Investment Conference
#BBHIC2024
. The presentation by CEO Cynthia Pussinen is available in the events section at
2
6
49
In December, our CEO, Dr. Philip Toleikis, presented a corporate overview at PBA’s Year in Review event. Tune in at the 24-minute mark of the video to learn more about the strides Sernova is making to provide a ‘functional cure’ for
#diabetes
:
3
7
48
.
@alexkeown
spoke with President & CEO, Dr. Philip Toleikis, about the updated positive interim data from the Phase 1/2
#diabetes
clinical trial of our Cell Pouch System, presented at
#ADA2022
by our collaborators from
@UChicagoMed
. Read in
@biospace
:
3
15
45
Piotr Witkowski, MD of
@UChicagoMed
will present a poster of our Phase 1/2 trial with the Cell Pouch System at the upcoming 2022
@ASTSChimera
Summer Winter Symposium, from August 4-7 in Miami.
2
7
45
Check out this article and watch the short video of our CEO, Dr. Philip Toleikis, providing an overview of our Cell Pouch System to Jim Cornall, Editor in Chief of
@Labiotech_eu
earlier this year during
#BIOEurope
. Read and watch here:
#T1D
#CellTherapy
5
8
46
Our President & CEO, Dr. Philip Toleikis, will participate in a fireside chat at the upcoming Truist Securities Cell Therapy Symposium, Symposia-cel, taking place on June 27 in New York. See our press release for more information: . $SVA $SEOVF
2
23
40
Sernova’s vision, is a future where chronic conditions are no longer insurmountable obstacles ❤️ Learn more at
#t1d
#biotech
#healthsci
2
12
48
Today,
@Evotec
presented new data from our partnership to develop and commercialize a potential ‘functional cure’ for
#T1D
at the 4th
@IPITAgroup
/
@harvardstemcell
/
@JDRF
Summit. Learn more details about what this data means here:
3
16
42
On April 24, Matthias Austen, PhD, of
@Evotec
will present the first data of Sernova’s Cell Pouch™ with Evotec’s iPSC derived islet-like clusters for
#T1D
at the 4th
@IPITAgroup
/
@harvardstemcell
/
@JDRF
Summit in Cambridge, MA. Learn more:
3
8
44
Sernova is committed to advancing the development of our Hemophilia A program, and has shown success in our pre-clinical models.
#biotech
6
15
48
Reminder – Today at the 4th
@IPITAgroup
/
@harvardstemcell
/
@JDRF
Summit in Cambridge, MA, Matthias Austen, PhD, of
@Evotec
, will present the first data of Sernova’s Cell Pouch™ with Evotec’s iPSC derived islet-like clusters for
#T1D
. Learn more here:
3
18
43
Look what we did!
Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List
Sernova awarded top performer status for two years standing
#Venture50
5
11
44
#Type1Diabetes
is a chronic disease in which the pancreas does not produce enough insulin for glucose to enter cells and produce energy. At Sernova, we are developing the Cell Pouch as a ‘functional cure’ for insulin-dependent
#diabetes
. Learn more:
4
11
43
Busy day of institutional meetings ahead, thanks to Leede Jones Gable for arranging.
3
5
44
On June 2, 2022, our common shares will begin trading on the Toronto Stock Exchange (TSX) and will be delisted from the TSX Venture Exchange. Read our press release to learn more: $SVA
2
7
44
November is
#DiabetesAwarenessMonth
. At Sernova, we aim to raise awareness of the unmet need for new treatment innovations for people living with
#diabetes
. Learn more from
@JDRF
about how you can get involved with Diabetes Awareness Month:
1
12
39
Our CEO, Dr. Philip Toleikis, was featured in
@PharmaScrip
’s
#ScripAsks
, sharing his thoughts about the future of
#biopharma
and the advancements of cell therapy to treat chronic diseases, including
#T1D
. Read his commentary here:
1
12
41
New article from JDRF on Sernova's Phase 1/2 T1D cell replacement therapy clinical trial update.
2
7
41
Our investor conference call scheduled for tomorrow, September 15, has been rescheduled to September 22. Our business update, strategy, and outlook call remains as scheduled for October 5. Learn more here: $SVA $SEOVF
1
24
37
As seen on
@BNNBloomberg
“Sernova’s promising results in its innovative clinical trials, mark a major advancement…offering hope to millions affected by the condition.”
Sernova is listed on the TSX: SVA, OTCQB: SEOVF and FSE/XETRA: PSH.
#biotech
#health
#t1d
#science
4
9
44
An informative article highlighting one of our main advantages over our competitors. The full retrievability of our Cell Pouch System™️
0
9
44
Our CEO, Dr. Philip Toleikis, sat down with
@JenatLFPress
of
@LFPress
to discuss the advancements in our Phase 1/2
#T1D
clinical trial and how a
#celltherapy
approach could provide a ‘functional cure’ for
#Type1Diabetes
. Read the article here:
2
10
41
Our CEO, Dr. Philip Toleikis, sat down with
@AyeshaR1202
on the
@Xtalks
Life Science Podcast to explain how our Cell Pouch System works and the clinical advances we are making to develop a ‘functional cure’ for patients with
#diabetes
. Listen here:
7
11
42
Check out this article by
@SeanWhooleyWTWH
of
@MassDevice
about the 2nd cohort of our Ph1/2 clinical trial in patients with
#Type1Diabetes
who suffer from
#HypoglycemiaUnawareness
. Read the article here:
#T1D
#diabetes
#CellTherapy
#RegenerativeMedicine
2
9
37
Recently our CEO, Dr. Toleikis, sat down with
@Pharmashot
to discuss our global strategic partnership with
@Evotec
and how it will contribute to the advancement of our Cell Pouch System as a ‘functional cure’ for insulin-dependent
#diabetes
. Read more:
1
7
41
Check out this article by
@MiriamETucker
in
@Medscape
, which highlights the recent presentation of our interim data at
#ADA22
as well as how our innovative Cell Pouch differs from other developments in the
#diabetes
space. Read the article here:
2
8
40
A recent article from
@diabetesdaily
spotlights our CEO, Cynthia Pussinen, and our novel
#CellTherapy
platform as a potential treatment for
#Type1Diabetes
(
#T1D
). Check out the article to learn more about our innovative approach:
1
12
41
Stay tuned for updated interim results on Sernova’s Phase I/II clinical trial to treat type 1 diabetes by Dr. Piotr Witkowski on January 13, 2022 at the American Society of Transplant Surgeons (ASTS) 22nd Annual “State of the Art” Winter Symposium.
3
8
40
Sernova Announces Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of its Therapeutic Approach for Thyroid Disease -
2
6
40
On November 13 and 14, our CEO, Cynthia Pussinen, and our VP of IR, Chris Barnes, will be in Vancouver and Edmonton meeting with investors. Visit our website to learn more about our novel
#CellTherapy
platform for
#ChronicDiseases
: $SVA $SEOVF
3
6
39
We are presenting a corporate overview highlighting our approach to finding functional cures for chronic debilitating diseases at several upcoming investor conferences. See press release for details and to register in advance here: $SVA
0
11
40
Our CEO, Dr. Philip Toleikis, shared his thoughts on the next treatment innovations being a ‘functional cure’ for chronic diseases in a recent
@pharmasalmanac
roundtable. Read his commentary here:
5
8
38
Our global strategic partnership with
@Evotec
was covered by
@alexkeown
of
@biospace
. Read the article to learn more about how the partnership will help progress our potential ‘functional cure’ for insulin-dependent
#diabetes
. Read here: $SVA
2
9
38
Last year we continued to advance our novel
#CellTherapy
platform for chronic diseases including
#T1D
,
#HemophiliaA
, and
#hypothyroidism
. Read today’s press release for a recap of our 2023 accomplishments and more on anticipated milestones for 2024: $SEOVF
1
7
40
Sernova is excited to announce that Jonathan Rigby has been appointed to its Board of Directors. With 30+ years of experience in biopharma as a President, CEO and CBO, Mr. Rigby brings a new level of expertise and success to Sernova’s Board. PRESS RELEASE:
1
7
41
#ICYMI
Andrea Park covered the news of our global strategic partnership with
@Evotec
in
@FierceBiotech
. Read the article to learn more:
#diabetes
$SVA
3
10
38
As 2023 comes to a close, we want to highlight some of our top milestones from this year. We are thankful for our partners and team members for making these accomplishments possible. We are looking forward to another successful year in 2024!
3
8
38
In parallel with our program for
#diabetes
, we are also developing our Cell Pouch System for use in patients with
#HemophiliaA
, a genetic disorder in which blood does not clot normally, leading to excessive bleeding. Learn more here:
1
10
37
On October 6, 2022, our President and CEO, Dr. Philip Toleikis, will be participating in the
@ROTHCapital
Inaugural Healthcare Opportunities Conference in New York, NY. Read our press release for more info: $SEOVF $SVA
2
1
37